Cited by 570Radiopharmaceutical Chemistry and ApplicationsRadioactivity and Radon MeasurementsMedical Imaging Techniques and Applications

The DOI matches its Crossref record; 363 of the 363 references it cites were found in a registry or an index.

MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy

Open access

Sgouros, George, Roeske, John C., McDevitt, Michael R., Palm, Stig, Allen, Barry J., Fisher, Darrell R., Brill, A. Bertrand, Song, Hong, Howell, Roger W., Akabani, Gamal·2010·Journal of Nuclear Medicine

DOI 10.2967/jnumed.108.058651PMC PMC5680544

Open this paper in CoChat — free account Open PDF

Abstract

The potential of alpha-particle emitters to treat cancer has been recognized since the early 1900s. Advances in the targeted delivery of radionuclides and radionuclide conjugation chemistry, and the increased availability of alpha-emitters appropriate for clinical use, have recently led to patient trials of radiopharmaceuticals labeled with alpha-particle emitters. Although alpha-emitters have been studied for many decades, their current use in humans for targeted therapy is an important milestone. The objective of this work is to review those aspects of the field that are pertinent to targeted alpha-particle emitter therapy and to provide guidance and recommendations for human alpha-particle emitter dosimetry.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2967/jnumed.108.058651

Cites

363 of 363 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

THE STOPPING AND RANGE OF IONS IN SOLIDS
Ziegler, J. F. (1988) · Elsevier eBooks · doi:10.1016/b978-0-12-780621-1.50005-8 · Cited by 9,077
THE STOPPING AND RANGE OF IONS IN SOLIDS
Ziegler, J. F. (1984) · Elsevier eBooks · doi:10.1016/b978-0-12-780620-4.50007-0 · Cited by 5,892
Recommendations of the International Commission on Radiological Protection
(1961) · Postgraduate Medical Journal · doi:10.1136/pgmj.37.425.168-b · Cited by 5,868
The Stopping and Range of Ions in Matter
Ziegler, J. F., & Biersack, J. P. (1985) · Springer eBooks · doi:10.1007/978-1-4615-8103-1_3 · Cited by 4,360
Radiobiology for the Radiologist.
(1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-80-3-438_1 · Cited by 3,498
The Stopping and Ranges of Ions in Matter
(1980) · Elsevier eBooks · doi:10.1016/c2013-0-02882-4 · Cited by 3,012
The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,228
International Commission on Radiological Protection
(1969) · Radiology · doi:10.1148/93.6.1298 · Cited by 2,148
Basic anatomical and physiological data for use in radiological protection: reference values
Valentin, J. (2002) · Annals of the ICRP · doi:10.1016/s0146-6453(03)00002-2 · Cited by 2,024
Report of the task group on reference man
(1979) · Annals of the ICRP · doi:10.1016/0146-6453(79)90123-4 · Cited by 1,715

Show all 363 references

Research works printed but not linked: 32

2005, J Nucl Med., 46, 199S
1990, Antibody Immunoconjugates Radiopharm., 4, 85
1997, Blood., 90, 2245
2006, Cancer Biother Radiopharm., 21, 395
2006, Cancer Biother Radiopharm., 21, 396
2006, J Nucl Med., 47, 1049
International Commission on Radiological Protection. Relative Biological Effectiveness (RBE), Quality Factor (Q), and Radiation Weighting Factor (wR). Philadelphia, PA: Elsevier; 2004. ICRP publication 92.
1964, Cancer Res., 24, 683
1995, J Nucl Med., 36, 259
1989, Lancet., 2, 650
1997, J Nucl Med., 38, 727
2000, J Nucl Med., 41, 941
2007, Ann ICRP., 37, 1
1994, J Nucl Med., 35, 521
1993, J Nucl Med., 34, 1811
1988, Cancer Res., 48, 7022
1992, J Nucl Med., 33, 2167
1994, J Nucl Med., 35, 303
Fisher DR. The microdosimetry of monoclonal antibodies labeled with alpha emitters. In: Schlafke-Stelson AT, Watson EE, eds. Fourth International Radiopharmaceutical Dosimetry Symposium. Oak Ridge, TN: Oak Ridge Associated Universities; 1986:26–36.
Kellerer AM. Analysis of patterns of energy deposition: a survey of theoretical relations in microdosimetry. In: Ebert HG, ed. Proceedings of the Second Symposium on Microdosimetry. Brussels, Belgium: Commission of European Communities; 1970:107–134.
1997, J Nucl Med., 38, 1923
2004, J Nucl Med., 45, 129
2001, J Nucl Med., 42, 1216
1999, J Nucl Med., 40, 37S
1975, J Nucl Med., 16, 248
1999, J Nucl Med., 40, 1935
2002, J Nucl Med., 43, 97
2003, J Nucl Med., 44, 774
2005, J Nucl Med., 46, 1171
1969, J Nucl Med., 10, 7
1999, J Nucl Med., 40, 1947
Goodhead DT. Talk 23, Alpha Emitters, from Session 6, Effects from Specific Sources of Internal Radiation. Presented at: CERRIE Workshop; July 21–23, 2003; Oxford, U.K.

Sorted by citations

Items 101–200 of 570

Radiopharmaceuticals heat anti-tumor immunity
Sun, Q., Li, J., Ding, Z., & Liu, Z. (2023) · Theranostics · doi:10.7150/thno.79806 · Cited by 43
Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during 177Lu/225Ac treatment in neuroendocrine tumors and metastatic prostate cancer
Dadgar, H., Pashazadeh, A., Norouzbeigi, N., Assadi, M., Albalooshi, B., Baum, R. P., Al‐Ibraheem, A., Haidar, M., Beheshti, M., Geramifar, P., et al. (2025) · Theranostics · doi:10.7150/thno.107963 · Cited by 43
Radium-223 as an Approved Modality for Treatment of Bone Metastases
Brito, A. E., & Etchebehere, E. (2020) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.11.005 · Cited by 43
Dosimetry for Optimized, Personalized Radiopharmaceutical Therapy
Graves, S. A., & Hobbs, R. F. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2020.07.008 · Cited by 43
Modelling and Dosimetry for Alpha-Particle Therapy
Sgouros, G., Hobbs, R. F., & Hong, S. (2011) · Current Radiopharmaceuticals · doi:10.2174/1874471011104030261 · Cited by 43
Self-citation
Image-based dosimetry for [225Ac]Ac-PSMA-I&T therapy and the effect of daughter-specific pharmacokinetics
Liubchenko, G., Böning, G., Zacherl, M. J., Rumiantcev, M., Unterrainer, L. M., Gildehaus, F. J., Brendel, M., Resch, S., Bartenstein, P., Ziegler, S. I., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06681-2 · Cited by 42
Preclinical optimization of antibody‐based radiopharmaceuticals for cancer imaging and radionuclide therapy—Model, vector, and radionuclide selection
Carter, L. M., Poty, S., Sharma, S. K., & Lewis, J. S. (2018) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3612 · Cited by 42
Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation
Yard, B. D., Gopal, P., Bannik, K., Siemeister, G., Hagemann, U. B., & Abazeed, M. E. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0859 · Cited by 41
Diffusing alpha-emitters radiation therapy: approximate modeling of the macroscopic alpha particle dose of a point source
Arazi, L. (2019) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ab5b73 · Cited by 41
Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
Batra, V., Samanta, M., Makvandi, M., Groff, D., Martorano, P., Elias, J., Ranieri, P., Tsang, M., Hou, C., Li, Y., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0400 · Cited by 40
Targeted Alpha Therapy: All We Need to Know about 225Ac’s Physical Characteristics and Production as a Potential Theranostic Radionuclide
Jalloul, W., Ghizdovăţ, V., Stolniceanu, C. R., Ionescu, T. M., Grierosu, I. C., Păvăleanu, I., Moscalu, M., & Ştefănescu, C. (2023) · Pharmaceuticals · doi:10.3390/ph16121679 · Cited by 40
Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered absorbed dose in a GATE model of bone marrow
Tranel, J., Feng, F. Y.-C., James, S. S., & Hope, T. A. (2020) · Physics in Medicine and Biology · doi:10.1088/1361-6560/abd3ef · Cited by 40
Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution?
Feuerecker, B., Kratochwil, C., Ahmadzadehfar, H., Morgenstern, A., Eiber, M., Herrmann, K., & Pomykala, K. L. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.265353 · Cited by 39
A case report of image-based dosimetry of bone metastases with Alpharadin (223Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-up
Pacilio, M., Ventroni, G., Cassano, B., Ialongo, P., Lorenzon, L., Castro, E. D., Recine, F., Sternberg, C. N., & Mango, L. (2015) · Annals of Nuclear Medicine · doi:10.1007/s12149-015-1044-9 · Cited by 39
Challenges of managing elderly men with prostate cancer
Jha, G. G., Anand, V., Soubra, A., & Konety, B. R. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.71 · Cited by 39
Glypican-3–Targeted 227Th α-Therapy Reduces Tumor Burden in an Orthotopic Xenograft Murine Model of Hepatocellular Carcinoma
Labadie, K. P., Hamlin, D. K., Kenoyer, A. L., Daniel, S. K., Utria, A. F., Ludwig, A. D., Kenerson, H. L., Li, L., Sham, J. G., Chen, D. L., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262562 · Cited by 38
Preclinical Evaluation of the Acute Radiotoxicity of the α-Emitting Molecular-Targeted Therapeutic Agent 211At-MABG for the Treatment of Malignant Pheochromocytoma in Normal Mice
Sudo, H., Tsuji, A. B., Sugyo, A., Nagatsu, K., Minegishi, K., Ishioka, N. S., Ito, H., Yoshinaga, K., & Higashi, T. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.04.008 · Cited by 38
Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model
Wickstroem, K., Karlsson, J., Ellingsen, C., Cruciani, V., Kristian, A., Hagemann, U. B., Bjerke, R. M., Ryan, O. B., Lindén, L., Mumberg, D., et al. (2019) · Pharmaceuticals · doi:10.3390/ph12040155 · Cited by 38
Human dosimetry of free 211At and meta-[211At]astatobenzylguanidine (211At-MABG) estimated using preclinical biodistribution from normal mice
Ukon, N., Zhao, S., Washiyama, K., Oriuchi, N., Tan, C., Shimoyama, S., Aoki, M., Kubo, H., Takahashi, K., & Ito, H. (2020) · EJNMMI Physics · doi:10.1186/s40658-020-00326-7 · Cited by 38
Nanoradiopharmaceuticals Based on Alpha Emitters: Recent Developments for Medical Applications
Trujillo-Nolasco, M., Morales-Ávila, E., Cruz-Nova, P., Katti, K. V., & Ocampo‐García, B. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081123 · Cited by 38
Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose211At-Labeled Anti-HER2 Single-Domain Antibody Fragment
Feng, Y., Meshaw, R. L., Zhao, X.-G., Jannetti, S. A., Vaidyanathan, G., & Zalutsky, M. R. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264071 · Cited by 38
The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer
Heinrich, D. A., Bektić, J., Bergman, A. M., Caffo, O., Cathomas, R. L., Chi, K. N., Daugaard, G., Keizman, D., Kindblom, J., Kramer, G., et al. (2017) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.08.020 · Cited by 37
The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis
Suominen, M. I., Wilson, T., Käkönen, S.-M., & Scholz, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163899 · Cited by 37
Immunoliposomal Delivery of 213Bi for α-Emitter Targeting of Metastatic Breast Cancer
Lingappa, M., Hong, S., Thompson, S., Bruchertseifer, F., Morgenstern, A., & Sgouros, G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4548 · Cited by 37
Self-citation
Nanostructure of Clustered DNA Damage in Leukocytes after In-Solution Irradiation with the Alpha Emitter Ra-223
Scherthan, H., Lee, J.-H., Maus, E., Schumann, S., Muhtadi, R., Chojowski, R., Port, M., Laßmann, M., Bestvater, F., & Hausmann, M. (2019) · Cancers · doi:10.3390/cancers11121877 · Cited by 37
Radioimmunotherapy for Treatment of Acute Leukemia
Bodet‐Milin, C., Kraeber‐Bodéré, F., Eugène, T., Guérard, F., Gaschet, J., Bailly, C., Mougin‐Degraef, M., Bourgeois, M., Faivre-Chauvet, A., Chérel, M., et al. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2015.10.007 · Cited by 36
Targeted alpha-particle therapy: imaging, dosimetry, and radiation protection
Laßmann, M., & Eberlein, U. (2018) · Annals of the ICRP · doi:10.1177/0146645318756253 · Cited by 36
Common strategic research agenda for radiation protection in medicine
European Federation of Radiographer Societies, European Society of Radiology (ESR), & European Society for Radiotherapy and Oncology (ESTRO) (2017) · Insights into Imaging · doi:10.1007/s13244-016-0538-x · Cited by 36
Effective treatment of ductal carcinoma in situ with a HER-2-targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer
Yoshida, T., Jin, K., Hong, S., Park, S., Huso, D. L., Zhang, Z., Han, L., Zhu, C., Bruchertseifer, F., Morgenstern, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8949 · Cited by 36
Self-citation
Radionuclides in radiation-induced bystander effect; may it share in radionuclide therapy?
Wideł, M. (2017) · Neoplasma · doi:10.4149/neo_2017_501 · Cited by 36
Small-scale (sub-organ and cellular level) alpha-particle dosimetry methods using an iQID digital autoradiography imaging system
Peter, R., Sandmaier, B. M., Dion, M., Frost, S. H. L., Santos, E. B., Kenoyer, A. L., Hamlin, D. K., Wilbur, D. S., Stewart, R. D., Fisher, D. R., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-22664-5 · Cited by 35
Self-citation
Targeted alpha therapy for glioblastoma
Kunikowska, J., Morgenstern, A., Pełka, K., Bruchertseifer, F., & Królicki, L. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1085245 · Cited by 35
Alpha-Emitters for Immuno-Therapy: A Review of Recent Developments from Chemistry to Clinics
Huclier‐Markai, S., Alliot, C., Varmenot, N., Cutler, C. S., & Barbet, J. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611212230002 · Cited by 35
The MIRD Schema for Radiopharmaceutical Dosimetry: A Review
ZANZONICO, P. B. (2024) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.123.265668 · Cited by 34
Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories
Yusufaly, T., Roncali, E., Brosch-Lenz, J., Uribe, C., Jha, A. K., Currie, G. M., Dutta, J., Fakhri, G. E., McMeekin, H., Pandit-Taskar, N. D., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.267927 · Cited by 34
Improving the dose–myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP
Pacilio, M., Ventroni, G., Basile, C., Ialongo, P., Becci, D., & Mango, L. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2552-2 · Cited by 34
α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation
Frost, S. H. L., Miller, B. W., Bäck, T. A., Santos, E. B., Hamlin, D. K., Knoblaugh, S. E., Frayo, S. L., Kenoyer, A. L., Storb, R. F., Press, O. W., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.162388 · Cited by 34
Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen)
Belli, M. L., Sarnelli, A., Mezzenga, E., Cesarini, F., Caroli, P., Iorio, V. D., Strigari, L., Cremonesi, M., Romeo, A., Nicolini, S., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.531660 · Cited by 34
Comparison of the Therapeutic Effects of [211At]NaAt and [131I]NaI in an NIS-Expressing Thyroid Cancer Mouse Model
Watabe, T., Liu, Y., Kaneda‐Nakashima, K., Sato, T., Shirakami, Y., Ooe, K., Toyoshima, A., Shimosegawa, E., Wang, Y., Haba, H., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169434 · Cited by 34
A review of recent advancements in Actinium‐225 labeled compounds and biomolecules for therapeutic purposes
Hassan, M., Bokhari, T. H., Lodhi, N. A., Khosa, M. K., & Usman, M. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14311 · Cited by 33
Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy
Lee, D., Li, M., Bednarz, B. P., & Schultz, M. K. (2018) · Radiation Research · doi:10.1667/rr15081.1 · Cited by 33
Systemic Radiotherapy of Bone Metastases With Radionuclides
Murray, I., & Du, Y. (2021) · Clinical Oncology · doi:10.1016/j.clon.2020.11.028 · Cited by 33
Tailoring radiotherapies and nanotechnology for targeted treatment of solid tumors
Khan, M. I., Batool, F., Ali, R., Zahra, Q. U. A., Wang, W., Li, S., Wang, G., Liu, L., Khan, S. U., Mansoor, M., et al. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2022.214757 · Cited by 32
Radiation Imagers for Quantitative, Single-particle Digital Autoradiography of Alpha- and Beta-particle Emitters
Miller, B. W. (2018) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2018.02.008 · Cited by 32
212Pb in targeted radionuclide therapy: a review
Scaffidi-Muta, J. M., & Abell, A. D. (2025) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-025-00362-7 · Cited by 31
Tandem Isotope Therapy with 225 Ac- and 177 Lu-PSMA-617 in a Murine Model of Prostate Cancer
Meyer, C. A. L., Stuparu, A. D., Lückerath, K., Calais, J., Czernin, J. G., Slavik, R., & Dahlbom, M. L. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265433 · Cited by 31
Optimizing radioimmunoconjugate delivery in the treatment of solid tumor
Huang, C., Pourgholami, M. H., & Allen, B. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.12.005 · Cited by 31
Self-citation
Pretargeted radioimmunotherapy of colorectal cancer metastases: models and pharmacokinetics predict influence of the physical and radiochemical properties of the radionuclide
Frampas, É., Maurel, C., Saëc, P. L., Mauxion, T., Faivre-Chauvet, A., Davodeau, F., Goldenberg, D. M., Bardiès, M., & Barbet, J. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1903-0 · Cited by 30
Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy
Divgi, C. R., Carrasquillo, J. A., Meredith, R. F., Seo, Y., Frey, E. C., Bolch, W. E., Zimmerman, B. E., Akabani, G., Jacobson, D., Brown, B., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.12.002 · Cited by 30
Self-citation
Utility of 211At-Trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α-Radioimmunotherapy Approach in a Clinically Relevant Mouse Model
Li, H. K., Morokoshi, Y., Kodaira, S., Kusumoto, T., Minegishi, K., Kanda, H., Nagatsu, K., & Hasegawa, S. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.249300 · Cited by 30
Radium dial workers: back to the future
Martinez, N. E., Jokisch, D. W., Dauer, L. T., Eckerman, K. F., Goans, R. E., Brockman, J. D., Tolmachev, S. Y., Avtandilashvili, M., Mumma, M. T., Boice, J. D., et al. (2021) · International Journal of Radiation Biology · doi:10.1080/09553002.2021.1917785 · Cited by 30
Imaging and dosimetry for alpha-particle emitter radiopharmaceutical therapy: improving radiopharmaceutical therapy by looking into the black box
Sgouros, G., Frey, E. C., Du, Y., Hobbs, R. F., & Bolch, W. E. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05583-x · Cited by 30
Self-citation
FZD10‐targeted α‐radioimmunotherapy with 225Ac‐labeled OTSA101 achieves complete remission in a synovial sarcoma model
Sudo, H., Tsuji, A. B., Sugyo, A., Harada, Y., Nagayama, S., Katagiri, T., Nakamura, Y., & Higashi, T. (2021) · Cancer Science · doi:10.1111/cas.15235 · Cited by 30
The Impact of Radiopharmaceutical Therapy on Renal Function
Park, E., Graves, S. A., & Menda, Y. (2022) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2022.02.004 · Cited by 30
Targeted α-therapy using 227Th-APOMAB and cross-fire antitumour effects
Staudacher, A. H., Bezak, E., Borysenko, A., & Brown, M. P. (2014) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000199 · Cited by 30
Design and Evaluation of 223Ra-Labeled and Anti-PSMA Targeted NaA Nanozeolites for Prostate Cancer Therapy–Part I
Czerwińska, M., Fracasso, G., Pruszyński, M., Bilewicz, A., Kruszewski, M. K., Majkowska‐Pilip, A., & Lankoff, A. (2020) · Materials · doi:10.3390/ma13173875 · Cited by 30
The Italian multicentre dosimetric study for lesion dosimetry in 223 Ra therapy of bone metastases: Calibration protocol of gamma cameras and patient eligibility criteria
Pacilio, M., Cassano, B., Chiesa, C., Giancola, S., Ferrari, M. E., Pettinato, C., Amato, E., Fioroni, F., Lorenzon, L., Pellegrini, R., et al. (2016) · Physica Medica · doi:10.1016/j.ejmp.2016.09.013 · Cited by 29
The Curies’ element: state of the art and perspectives on the use of radium in nuclear medicine
Franchi, S., Asti, M., Marco, V. D., & Tosato, M. (2023) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-023-00220-4 · Cited by 29
Monte Carlo calculation of the maximum therapeutic gain of tumor antivascular alpha therapy
Huang, C., Oborn, B. M., Guatelli, S., & Allen, B. (2012) · Medical Physics · doi:10.1118/1.3681010 · Cited by 28
Self-citation
Synthesis and Evaluation of Astatinated N-[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide Immunoconjugates
Aneheim, E., Gustafsson, A., Albertsson, P., Bäck, T. A., Jensen, H. J., Palm, S., Svedhem, S., & Lindegren, S. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00664 · Cited by 28
Self-citation
TAG-72–Targeted α-Radionuclide Therapy of Ovarian Cancer Using 225Ac-Labeled DOTAylated-huCC49 Antibody
Minnix, M., Li, L., Yazaki, P. J., Miller, A. D., Chea, J., Poku, E. K., Liu, A., Wong, J. Y. C., Rockne, R. C., Colcher, D. M., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.243394 · Cited by 27
Radiopharmacokinetic modelling and radiation dose assessment of 223Ra used for treatment of metastatic castration-resistant prostate cancer
Höllriegl, V., Petoussi-Henss, N., Hürkamp, K., Ramos, J. C. O., & Li, W. B. (2021) · EJNMMI Physics · doi:10.1186/s40658-021-00388-1 · Cited by 27
Targeted Radionuclide Therapy in Glioblastoma
Zhao, X., Jakobsson, V., Tao, Y., Zhao, T., Wang, J., Khong, P., Chen, X. S., & Zhang, J. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c07850 · Cited by 27
Radioimmunotherapy for Prostate Cancer—Current Status and Future Possibilities
Axelsson, S. E., Timmermand, O. V., Bjartell, A. S., Strand, S., & Elgqvist, J. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2015.10.005 · Cited by 27
Therapeutic targeting of tumor hypoxia and necrosis with antibody α-radioconjugates
Staudacher, A. H., Liapis, V., & Brown, M. P. (2018) · Antibody Therapeutics · doi:10.1093/abt/tby010 · Cited by 27
Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344
Wickstroem, K., Hagemann, U. B., Kristian, A., Ellingsen, C., Sommer, A., Ellinger-Ziegelbauer, H. C., Wirnitzer, U., Hagelin, E.-M., Larsen, A., Smeets, R., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.06.2508 · Cited by 27
Monte Carlo simulation of irradiation and killing in three-dimensional cell populations with lognormal cellular uptake of radioactivity
Howell, R. W., Rajon, D. A., & Bolch, W. E. (2011) · International Journal of Radiation Biology · doi:10.3109/09553002.2011.602379 · Cited by 27
Self-citation
The Evolving Coordination Chemistry of Radiometals for Targeted Alpha Therapy
Grieve, M. L., & Paterson, B. M. (2021) · Australian Journal of Chemistry · doi:10.1071/ch21184 · Cited by 28
Heterogeneity of dose distribution in normal tissues in case of radiopharmaceutical therapy with alpha-emitting radionuclides
Li, W. B., Bouvier‐Capely, C., Vargas, C. S., Andersson, M., & Madas, B. G. (2022) · Radiation and Environmental Biophysics · doi:10.1007/s00411-022-01000-5 · Cited by 26
From Concept to Regulatory Drug Approval: Lessons for Theranostics
Perera, M., & Morris, M. J. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263301 · Cited by 26
Reining in Radium for Nuclear Medicine: Extra-Large Chelator Development for an Extra-Large Ion
Simms, M. E., Sibley, M. M., Driscoll, D. M., Kertész, V., Damron, J. T., Ivanov, A. S., White, F. D., & Thiele, N. A. (2023) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.3c02985 · Cited by 27
Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review
Gape, P. M. D., Schultz, M. K., Stasiuk, G. J., & Terry, S. Y. A. (2024) · Pharmaceuticals · doi:10.3390/ph17030334 · Cited by 26
Alpha and Beta Radiation for Theragnostics
Hong, S., & Sgouros, G. (2024) · PET Clinics · doi:10.1016/j.cpet.2024.03.006 · Cited by 26
Self-citation
Possibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using 211At-CXCR4 monoclonal antibody
Oriuchi, N., Aoki, M., Ukon, N., Washiyama, K., Tan, C., Shimoyama, S., Nishijima, K., Takahashi, K., Ito, H., Ikezoe, T., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-63557-9 · Cited by 26
Evaluation of [225Ac]Ac-DOTA-anti-VLA-4 for targeted alpha therapy of metastatic melanoma
Cortez, A. G., Josefsson, A., McCarty, G. W., Shtekler, A., Rao, A., Austin, Z., & Nedrow, J. R. (2020) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2020.07.006 · Cited by 26
Challenges and opportunities in developing Actinium-225 radiopharmaceuticals
Dhiman, D., Vatsa, R., & Sood, A. K. (2022) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001594 · Cited by 25
Actinium-225 Targeted Agents: Where Are We Now?
Mourtada, F., Tomiyoshi, K., Sims‐Mourtada, J., Mukai-Sasaki, Y., Yagihashi, T., Namiki, Y., Murai, T., Yang, D. J., & Inoue, T. (2023) · Brachytherapy · doi:10.1016/j.brachy.2023.06.228 · Cited by 25
Immunological effects of radiopharmaceutical therapy
Shea, A. G., Idrissou, M. B., Torres, A. I., Chen, T., Hernandez, R., Morris, Z. S., & Sodji, Q. H. (2024) · Frontiers in Nuclear Medicine · doi:10.3389/fnume.2024.1331364 · Cited by 25
Clinical Theranostics in Recurrent Gliomas: A Review
Hoggarth, A. R., Muthukumar, S., Thomas, S. M., Crowley, J., Kiser, J. W., & Witcher, M. R. (2024) · Cancers · doi:10.3390/cancers16091715 · Cited by 25
Alpha Particle Emitter Radiolabeled Antibody for Metastatic Cancer: What Can We Learn from Heavy Ion Beam Radiobiology?
Hong, S., Senthamizhchelvan, S., Hobbs, R. F., & Sgouros, G. (2012) · Antibodies · doi:10.3390/antib1020124 · Cited by 25
Self-citation
Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with 211At-MX35-F(ab′)2: Influence of Absorbed Tumor Dose and Effect on Long-Term Survival
Bäck, T. A., Chouin, N., Lindegren, S., Kahu, H., Jensen, H. J., Albertsson, P., & Palm, S. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178327 · Cited by 25
Self-citation
Targeted alpha therapy with 212Pb or 225Ac: Change in RBE from daughter migration
Ackerman, N. L., Rosales, L. D. L. F., Falzone, N., Vallis, K. A., & Bernal, M. A. (2018) · Physica Medica · doi:10.1016/j.ejmp.2018.05.020 · Cited by 25
Radiopharmaceutical Chemistry and Drug Development—What's Changed?
Kunos, C. A., Mankoff, D. A., Schultz, M. K., Graves, S. A., & Pryma, D. A. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2020.07.006 · Cited by 24
Transport-driven engineering of liposomes for delivery of α-particle radiotherapy to solid tumors: effect on inhibition of tumor progression and onset delay of spontaneous metastases
Prasad, A. G., Nair, R., Bhatavdekar, O., Howe, A. K., Salerno, D., Sempkowski, M., Josefsson, A., Pacheco‐Torres, J., Bhujwalla, Z. M., Gabrielson, K. L., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05406-z · Cited by 24
Self-citation
Differential responses to 223Ra and Alpha-particles exposure in prostate cancer driven by mitotic catastrophe
Liberal, F. D. C. G., Moreira, H., Redmond, K. M., O’Sullivan, J. M., Alshehri, A. H. D., Wright, T., Dunne, V. L., Campfield, C., Biggart, S., McMahon, S. J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.877302 · Cited by 24
Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma
Makvandi, M., Samanta, M., Martorano, P., Lee, H., Gitto, S. B., Patel, K., Groff, D., Pogoriler, J. E., Martínez, D., Riad, A., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-04209-8 · Cited by 24
Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review
Shah, H., Ruppell, E., Bokhari, R., Aland, P., Lele, V. R., Ge, C., & McIntosh, L. (2023) · European Journal of Radiology Open · doi:10.1016/j.ejro.2023.100477 · Cited by 24
Evaluation of Candidate Theranostics for227Th/89Zr Paired Radioimmunotherapy of Lymphoma
Abou, D. S., Longtine, M. S., Fears, A., Benabdallah, N., Unnerstall, R., Johnston, H. E., Shim, K., Hasson, A., Zhang, H., Ulmert, D., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264979 · Cited by 24
Alpha‐emitters and targeted alpha therapy in cancer treatment
Zhang, J., Qin, S., Yang, M., Zhang, X., Zhang, S., & Yu, F. (2023) · iRadiology · doi:10.1002/ird3.30 · Cited by 24
RYZ101 (Ac-225 DOTATATE) Opportunity beyond Gastroenteropancreatic Neuroendocrine Tumors: Preclinical Efficacy in Small-Cell Lung Cancer
Han, G., Hwang, E., Lin, F., Clift, R., Kim, D., Guest, M., Bischoff, E. D., Moran, S. E., & Li, G. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0029 · Cited by 24
Targeted Radionuclide Therapy: Proceedings of a Joint Workshop Hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging
Fahey, F. H., Zukotynski, K., Capala, J., & Knight, N. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.135178 · Cited by 24
Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation
Nguyen, N. C., Shah, M. A., Appleman, L. J., Parikh, R. A., & Mountz, J. M. (2016) · International Journal of Molecular Imaging · doi:10.1155/2016/2568031 · Cited by 24
Targeted Radionuclide Therapy of Painful Bone Metastases: Past Developments, Current Status, Recent Advances and Future Directions
Dash, A. K., Das, T., & Knapp, F. F. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190201142814 · Cited by 24
Towards elucidating the radiochemistry of astatine – Behavior in chloroform
Aneheim, E., Palm, S., Jensen, H. J., Ekberg, C. H., Albertsson, P., & Lindegren, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-52365-5 · Cited by 24
Self-citation
225Ac-PSMA-617 radioligand posttherapy imaging in metastatic castrate-resistant prostate cancer patient using 3 photopeaks.
Vatsa, R., Sood, A., Vadi, S. K., Das, C. K., Kaur, K., Parmar, M., & Mittal, B. R. (2020) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003031 · Cited by 23
Activity quantification and dosimetry in radiopharmaceutical therapy with reference to 177Lutetium
Ramonaheng, K., Qebetu, M., Ndlovu, H., Swanepoel, C., Smith, L., Mdanda, S., Mdlophane, A. H., & Sathekge, M. M. (2024) · Frontiers in Nuclear Medicine · doi:10.3389/fnume.2024.1355912 · Cited by 23
Emerging innovations in theranostics for pancreatic neuroendocrine tumors
Karimi, A., Bogdani, C., O’Dwyer, E., & Siolas, D. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00938-1 · Cited by 23
Alpha‐Emitter Radium‐223 Induces STING‐Dependent Pyroptosis to Trigger Robust Antitumor Immunity
Yang, M., Liu, H., Lou, J., Zhang, J., Zuo, C., Zhu, M., Zhang, X., Yin, Y., Zhang, Y., Qin, S., et al. (2023) · Small · doi:10.1002/smll.202307448 · Cited by 24
Radionuclide Therapy for Osseous Metastases in Prostate Cancer
Abi‐Ghanem, A. S., McGrath, M. A., & Jacene, H. A. (2014) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2014.07.006 · Cited by 23
Is Hypoxia a Factor Influencing PSMA-Directed Radioligand Therapy?—An In Silico Study on the Role of Chronic Hypoxia in Prostate Cancer
Birindelli, G., Drobnjaković, M., Morath, V., Steiger, K., D’Alessandria, C., Gourni, E., Afshar‐Oromieh, A., Weber, W., Rominger, A., Eiber, M., et al. (2021) · Cancers · doi:10.3390/cancers13143429 · Cited by 23

Authors: Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G.
Affiliations: Johns Hopkins University (US)
Loyola University Medical Center (US)
Memorial Sloan Kettering Cancer Center (US)
International Atomic Energy Agency (AT)
Pacific Northwest National Laboratory (US)
Vanderbilt University (US)
Rutgers, The State University of New Jersey (US)
Texas A&M University (US)
ORCID: Roeske, John C.
McDevitt, Michael R.
Palm, Stig
Fisher, Darrell R.
Brill, A. Bertrand
Howell, Roger W.
Akabani, Gamal
Venue: Journal of Nuclear Medicine
Publisher: Society of Nuclear Medicine
Published: 2010-01-15
Volume: 51
Issue: 2
Pages: 311-328
ISSN: 0161-5505 (ISSN-L)
2159-662X
DOI: 10.2967/jnumed.108.058651
PMC: PMC5680544
OpenAlex: W2018649196
Cited by: 552
References: 363
Citations by year: 2026: 60 · 2025: 58 · 2024: 50 · 2023: 54 · 2022: 50 · 2021: 50 · 2020: 39 · 2019: 34 · 2018: 44 · 2017: 17 · 2016: 21 · 2015: 10 · 2014: 25 · 2013: 11 · 2012: 16
FWCI: 9.79
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Nuclear Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute on Aging (P50AG005136)
National Cancer Institute (R01CA109234, R41CA117599, P30CA008748)
National Institute of Biomedical Imaging and Bioengineering (R01EB001994)
National Center for Research Resources (R43RR015155)
Topics: Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Physical Sciences › Physics and Astronomy › Radiation › Radioactivity and Radon Measurements
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords: alpha-emitting radionuclides, targeted alpha therapy, radiation biology, dosimetry, radionuclide conjugation, radiopharmaceuticals, cancer therapy
MeSH terms: Alpha Particles, Cell Survival, Clinical Trials as Topic, Dose-Response Relationship, Radiation, Female, Humans, Male, Neoplasms, Neoplasms, Radiation-Induced, Pamphlets, Radiation-Protective Agents, Radiobiology, Radioisotopes, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted, Relative Biological Effectiveness, Societies, Medical, Cell Death

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks